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Abstract
Introduction: Although surgical resection is necessary, it is not sufficient for long-
term survival in pancreatic ductal adenocarcinoma (PDAC). We sought to evaluate
survival after up-front surgery (UFS) in anatomically resectable PDAC in the context
of three critical factors: (A) margin status; (B) CA19-9; and (C) receipt of adjuvant
chemotherapy.
Methods: The National Cancer Data Base (2010–2015) was reviewed for clinically
resectable (stage 0/I/II) PDAC patients. Surgical margins, pre-operative CA19-9, and
receipt of adjuvant chemotherapy were evaluated. Patient overall survival was stratified based on these factors and their respective combinations. Outcomes after UFS
were compared to equivalently staged patients after neoadjuvant chemotherapy on an
intention-to-treat (ITT) basis.
Results: Twelve thousand and eighty-nine patients were included (n = 9197 UFS,
n = 2892 ITT neoadjuvant). In the UFS cohort, only 20.4% had all three factors (median OS = 31.2 months). Nearly 1/3rd (32.7%) of UFS patients had none or only
one factor with concomitant worst survival (median OS = 14.7 months). Survival
after UFS decreased with each failing factor (two factors: 23 months, one factor:
15.5 months, no factors: 7.9 months) and this persisted after adjustment. Overall survival was superior in the ITT-neoadjuvant cohort (27.9 vs. 22 months) to UFS.
Conclusion: Despite the perceived benefit of UFS, only 1-in-5 UFS patients actually
realize maximal survival when known factors highly associated with outcomes are assessed. Patients are proportionally more likely to do worst, rather than best after UFS
treatment. Similarly staged patients undergoing ITT-neoadjuvant therapy achieve
survival superior to the majority of UFS patients. Patients and providers should be
aware of the false perception of ‘optimal’ survival benefit with UFS in anatomically
resectable PDAC.

This work has is not under consideration for publication elsewhere. The work has been presented orally at the 58th annual meeting of the Society for Surgery
of the Alimentary Tract as part of Digestive Disease Week in Chicago, IL May 2017 and Pancreas Club May 2019.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original
work is properly cited.
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Cancer Medicine. 2021;00:1–11.		
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IN T RO D U C T IO N

Surgical resection is necessary for long-
term survival in
pancreatic ductal adenocarcinoma (PDAC) and is therefore
perceived as the optimal initial treatment strategy in the
15%–20% of patients presenting with anatomically ‘resectable’ tumors.1 However, despite curative-intent, surgery is
not sufficient for durable long-term survival as the majority of patients undergoing resection develop postoperative
recurrence.2 The concept of ‘borderline’ resectability was
introduced to identify those patients that may benefit from
neoadjuvant therapy prior to resection due to increased risk
of positive margins with upfront resection.3 Although a neoadjuvant strategy is increasingly utilized in anatomically borderline PDAC, there is no consensus on the benefit of this
approach in anatomically resectable tumors, despite increased
interest in such an approach.4–6 What is known based on previously established data, is that specific factors profoundly
influence post-operative survival in those patients undergoing upfront surgery (UFS): margin status, CA19-9 levels, and
receipt of adjuvant chemotherapy. Despite improvements in
cross-sectional radiologic imaging, at least 20%–30% of anatomically resectable patients will have a positive margin (R1)
resection with consequent approximately 50% decrease in
median survival.7,8 The importance of elevated CA19-9 levels as a surrogate of occult metastatic disease and early postoperative recurrence is now recognized.9–12 Finally, multiple
trials have demonstrated the survival benefit of adjuvant systemic chemotherapy in resectable pancreatic cancer, suggesting the likelihood of occult residual disease in the majority
of patients undergoing curative upfront resection. However,
many patients do not ultimately begin or complete this recommended therapy.13–19 Although there have been several
large database studies comparing upfront resection (UFS)
with neoadjuvant therapy in anatomically resectable PDAC,
none have specifically evaluated outcomes in the context of
these important factors that profoundly and independently
impact survival.4,5,20–22
In the era of UFS for PDAC, improvements in overall
survival have plateaued. Thus, although surgery is known to
be necessary for long-term survival in patients with pancreatic cancer, it is not sufficient to guarantee durable survival
due to the influence of the factors outlined above. Due to the
extensive resources required to conduct randomized trials in
oncology, the challenges presented by the inability to blind
patients to a neoadjuvant versus upfront-surgery treatment
strategy, and the time which would be required to measure
survival outcomes, such studies are difficult to appropriately

design and accrue practically. Consequently, the utilization
of observational data can facilitate the current critical evaluation of the utility of UFS in localized PDAC.
Therefore, the present study is designed to assess the
combinatorial frequency of the absence or presence of the
above-
mentioned survival factors in patients with localized, anatomically resectable pancreatic cancer undergoing
a surgery-first approach. Such an analysis to our knowledge
has not been performed before. In contrast to prior work, this
study does not merely intend to directly compare UFS against
neoadjuvant, but rather seeks to add context by the determination of the ‘proportion’ of patients that are able to achieve
optimal outcomes with upfront resection—a critical measure
for population oncology. The aim was to assess the individual and combined influence of these factors on postoperative
survival. For contrast, outcomes were compared to similarly
staged patients undergoing neoadjuvant systemic chemotherapy on an intent-to-treat basis, including patients who did not
proceed to resection.
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PATIENTS AND M ETHODS

This study is a retrospective cohort analysis of the National
Cancer Data Base (NCDB) participant user file (PUF) of
patients undergoing treatment for localized (AJCC Stage
0/I/II) pancreatic adenocarcinoma from 2010 to 2015. The
Mayo Clinic Institutional Review Board has deemed analysis of the NCDB PUF exempt from review. The NCDB
contains over 30 million individual cancer cases collected
by more than 1500 Commission on Cancer (CoC) approved facilities across the United States (US) and reportedly captures over 70% of newly diagnosed cases of cancer
in the US.23
Patients with PDAC were identified using International
Classification of Diseases for Oncology, third edition (ICD-
O-3) topography (C25.0–C25.9) and histology (8140–8145,
8211, 8230, 8260–
8263, 8290, 8310, 8480–
8481, 8500–
8508, 8521–8523, 8570–8576) codes. Included patients were
diagnosed and treated at the reporting facility. Patients diagnosed with multi-site cancer and those missing pathologic
or follow-up data were excluded. Summary staging was assessed using the sixth or seventh edition AJCC staging manual according to the year of the case. Curative intent surgery
included surgery of primary site codes 21–89 which includes
pancreaticoduodenectomy, distal partial pancreatectomy,
total pancreatectomy, and pancreatectomy NOS. Patients
with surgical codes 0 (no surgery), 90 (surgery, NOS), and
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99 (unknown) were excluded. Patient data were assessed for:
(A) negative (R0) margins; (B) normal pre-op CA19-9 levels (<37 U/ml), evaluated according to previously published
methods12; and (C) receipt of any adjuvant chemotherapy
(single or multi-agent). Patients undergoing UFS were scored
based on the absence (score = 0) or presence (score = 1) of
any combination of these factors (total score = 0–3) and
overall survival (OS) was stratified by various factorial combinations. We then compared these outcomes with similarly
staged patients undergoing neoadjuvant chemotherapy on an
intention to treat (ITT) basis, including those treated with
neoadjuvant therapy but who did not subsequently undergo
curative-intent surgery. Missing data were handled with case
exclusion or indicator variables. A STROBE-compliant diagram showing all patients included and excluded is provided
in Figure 1.

2.1
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Statistical analysis

Normally distributed continuous data were expressed as
mean and standard deviation and interrogated for equivalence
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with the two-tailed Student’s t-test. Non-normally distributed
continuous data were expressed as median (inter-quartile
range) interrogated for equivalence with the Mann–Whitney
U test. Pearson’s chi-squared tests were used to interrogate
uniformly distributed categorical variables and Fisher’s exact
test was used for categorical variables with non-uniform distribution. Unadjusted survival analysis was performed using
the method of Kaplan and Meier with survival defined as
the time in months from date of surgery to death with THE
censorship of patients alive at last follow-up. Unadjusted
survival estimates were compared by means of the log-rank
test. The NCDB does not provide data on progression or recurrence, therefore survival is reported overall. To estimate
the impact of procedure type and adjuvant therapy receipt
on survival, we constructed a multivariable Cox proportional
hazards model adjusted for age, gender, race, Charlson-Deyo
comorbidity score, grade, presence of lymphovascular invasion, margin status, receipt of radiation, receipt of chemotherapy, type of surgery, and type of facility. A significance
level of 0.05 was used for all comparisons. Statistical analysis was performed with R version 3.5.2 (‘Eggshell Igloo’—R
Foundation for Statistical Computing, www.r-project.org).

Primary cancer of pancreas in NCDB from
2010-2015 (n= 340,906)
Excluded (n= 328,817)
♦

Not first cancer diagnosis (n= 23,825)

♦

Not treated at reporting facility (n= 54,681)

♦

No vital status information (n= 22,242)

♦

No follow up date (n= 184)

♦

Palliative Care (n=20,370)

♦

CA 19-9 Unknown (n=117,267)

♦

Chemotherapy Status Unknown (n= 2,412)

♦

Margin Status Unknown (n= 1,230)

♦

Not pancreatic ductal adenocarcinoma (n= 34,308)

♦

Stage III, IV, or Unknown (n= 43,504)

♦

Topography not C25.0-25.2 (n= 2,315)

♦

Procedure not PD or DPP (n= 4,479)

Included in Survival and Staging
Analysis (n= 12,089)

F I G U R E 1 STROBE diagram of
cohorts included and excluded

|

Surgery First

ITT Neoadjuvant

(n= 9,197)

(n= 2,892)
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R E S U LTS

Twelve thousand and eighty-
nine total patients were included, of which 9197 (76%) underwent UFS and 2892
(24%) received neoadjuvant chemotherapy with a plan to
proceed with curative surgery (ITT). Descriptive characteristics and details for each cohort are shown in Table 1. UFS
patients were slightly older (median age at diagnosis 66 vs.
63), less often caucasian (84.4% vs. 87.2%), had higher comorbidity (64.9% vs. 67.4% Charlson score 0), and were less
often treated in the academic setting (56.8% vs. 65.5%, all
p < 0.001) compared to the ITT neoadjuvant cohort. There
was no difference in gender between the groups. Differences
in tumor location between groups were small, but UFS patients were less likely to have their tumor in the head of the
pancreas.
Among UFS patients, 76.3% had negative margin resections, 31.8% had non-elevated CA19-9 levels, and 69.6% received adjuvant chemotherapy. Only 20.4% of UFS patients
had all three of these survival factors that resulted in the best
median OS of 31.2 months (Table 2). In contrast, nearly 1/3rd
of patients (32.7%) treated with UFS had either one or none of
these survival factors, and this was associated with the worst
survival (median OS = 14.7 months). Unadjusted median
survival decreased with the absence of each survival factor
(23.4 months for two factors, 46.8% of patients; 15.5 months
for one factor, 27.9% of patients; and 7.9 months for no factors, 4.9% of patients), and this survival varied by specific
factorial combinations as outlined in Table 2. Figure 2 graphically shows the unadjusted overall survival of the UFS patients stratified by their total factor score. The decrease in
survival with the absence of each factor persisted even after
adjustment for other clinically significant variables (age, gender, race, comorbidity score, node status, tumor grade, type
of facility—Figure 3).
Over the course of the study period, the proportion of
patients undergoing ITT neoadjuvant chemotherapy significantly increased from 18.6% in 2010 to 30.7% in 2014, and
these patients were compared to UFS patients on clinical
stage (0/I/II) at presentation (Table 1). Compared to UFS patients, the ITT neoadjuvant cohort was slightly less likely to
have elevated CA 19-9 (62.8% vs. 69.2%). ITT neoadjuvant
patients were more likely to have clinical stage II disease
(55.4% vs. 39.1%) and higher rates of clinically node-positive
disease (29.5% vs. 21.0%) at diagnosis. In spite of this, final
pathologic markers for ITT neoadjuvant patients undergoing resection skewed favorably compared to the UFS cohort
with ITT patients much less likely to have final pathologic
stage II disease after resection (79.7% vs. 91.2%), less positive nodes (47.6% vs. 70.7%), lower lymphovascular invasion (34.7% vs. 53.4%), and lower rate of positive surgical
margins (16.7% vs. 23.7%) suggesting treatment response to
neoadjuvant therapy. Unplanned readmission within 30 days

was more common (7.9% vs. 5.9%) and the mortality rate
at 90 days after surgery was higher (5.3% vs. 4.5%) in the
UFS cohort compared to those in the ITT neoadjuvant cohort. The overall survival for all patients in this study was
23.5 months and was superior in the ITT neoadjuvant cohort
(27.9 months) versus UFS (22.0 months). Median OS in the
ITT neoadjuvant cohort was better than the survival in 80%
of UFS patients. All comparisons reported above met statistical significance criteria.
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DISCUSSION

Despite the perceived benefit of a surgery-first strategy in patients with localized, resectable PDAC,24 only 1-in-5 (20%)
patients actually achieved maximum survival in the context
of these three established predictive factors (margin status,
pre-op CA19-9 levels, and receipt of adjuvant chemotherapy). Survival decreased with each failing factor and a high
proportion of patients (34%) were identified with only one
or no factors with the resultant worst survival overall. The
analysis confirms that UFS, although perceived as maximally
beneficial, is in fact highly dependent on these specific factors, which apart from preoperative CA19-9 levels, cannot be
known or guaranteed prior to resection. Therefore, despite the
dominant perception of the benefit of UFS in anatomically
resectable pancreatic cancer, the reality is that the majority
of patients have a higher likelihood of actually doing the
worst, rather than the best in the context of these factors with
upfront resection. This is a probability that most surgeons
and patients likely do not consider or realize, and should give
pause to such a practice. These data also further highlight the
potential benefits of neoadjuvant treatment sequencing, even
in patients with surgically resectable PDAC.25 These findings have an impact on treatment standards and guidelines.
In this study, 23.7% of patients had positive margins on
final pathologic analysis, consistent with rates from previous adjuvant trials in resectable PDAC. In fact, this rate of
margin positivity was lower than the ESPAC-III data (35%),
but higher than CONKO (17%) and ESPAC-1 (18%).15,26,27
CA19-9 was elevated in over 60% of patients in this cohort,
and this is also highly consistent with rates reported in prior
studies.8,28,29 Prior work has shown that any elevation of
CA19-9 above normal is associated with detrimental stage-
matched survival outcomes, and that the only treatment sequence which ameliorates the decreased survival associated
with CA19-9 elevation is neoadjuvant systemic chemotherapy.12 Despite its known negative influence as well as reports
from multiple centers on specific optimal CA19-9 cutoff levels, this important and predictive survival factor continues to
be under-utilized in otherwise resectable PDAC patients—
demonstrated by prior data revealing that only approximately
25% of patients in national datasets even have pre-operative
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TABLE 1
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Cohort demographics, pathologic characteristics, and outcomes
Surgery-first (UFS)

Neoadjuvant (ITT)

n = 9197

n = 2892

Median age [IQR]

66.0 [59.0, 74.0]

63.0 [56.0, 69.0]

Female sex

48.8%

47.6%

Race
Caucasian

84.4%

0.286

87.2%

African American

10.8%

9.2%

4.8%

3.6%

0

64.9%

67.4%

1

29.0%

28.0%

2+

6.1%

4.6%

Charlson Deyo score

0.028

Facility type

<0.001

Community

3.3%

2.8%

Comprehensive community

27.9%

21.7%

Academic/research

56.8%

65.5%

Integrated network

12.0%

9.9%

Year of diagnosis

<0.001

2010

18.7

13.6

2011

19.6

16.7

2012

20.5

19.3

2013

21.1

22.3

2014

20.0

28.1

34.4%

23.6%

Clinical stage (%)

<0.001

Stage II

39.1%

55.4%

Missing

26.5%

21.0%

Final path stage (%)

<0.001

Stage I

8.8%

20.3%

Stage IIA

21.5%

32.2%

Stage IIB

69.7%

47.5%

Location
Head

<0.001
0.002

Other

Stage I

p

<0.001
75.0%

78.4%

Body/tail

15.5%

11.3%

Other/NOS

9.5%

10.3%

Median tumor size (cm) [IQR]

3.2 [2.5, 4.1]

3.2 [2.5, 4.1]

CA 19-9 elevated above normal

69.2%

62.8%

Tumor size category

0.762
<0.001
<0.001

<2 cm

10.3%

9.3%

>2 cm

88.5%

87.3%

Missing

1.2%

3.5%

62.6%

63.9%

cN status
cN0
cN1

21.0%

29.5%

Missing or unstaged

16.4%

6.6%
(Continues)
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(Continued)
Surgery-first (UFS)

Neoadjuvant (ITT)

p

pN1 status (% of available)

70.7%

47.6%

<0.001

High grade (% of available)

37.3%

32.2%

<0.001

Lymphovascular invasion (% of available)

53.4%

34.7%

<0.001

Positive margin (% of available)

23.7%

16.7%

<0.001

Any radiation

31.7%

62.5%

<0.001

Adjuvant chemotherapy

69.6%

33.8%

<0.001

30-day readmission

7.9%

5.9%

<0.001

90-day mortality

5.3%

4.5%

<0.001

TABLE 2

Mortality hazard and unadjusted median overall survival based on the score/treatment category

Treatment strategy

Score category

% (N) of Pts.

Unadjusted median overall
survival (months)

Surgery-first

ABC score = 3

20.4% (1876)

31.0

AC only, score = 2

32.4% (2977)

ITT neoadjuvant

46.8% (4301)

79.6% (7321)

23.9

AB only, score = 2

8.4% (772)

23.3

BC only, score = 2

6.0% (552)

21.3

C only, score = 1

10.9% (999)

A only, score = 1

14.7% (1349)

15.2

B only, score = 1

2.4% (217)

10.4

None score = 0

4.9% (455)

7.9

—

100% (2892)

27.9

32.8% (3020)

17.5

23.4

19.6

14.7

Note:: A = Negative resection margin; B = Normal CA 19-9; C = Receipt of adjuvant chemotherapy.

CA19-9 measured.12 In the present study, 30.4% of patients
did not receive adjuvant chemotherapy, and this is similar
to the proportion observed in other studies of adjuvant therapy in PDAC.29–31 Although prior analysis using the NCDB
dataset compared survival outcomes of surgery-first versus
neoadjuvant treatment in resectable PDAC,5,20–22 this is the
first study to specifically compare outcomes of each treatment sequence in the context of these critical and previously
established survival factors in resectable patients. Therefore,
this analysis provides much-needed clinical insight into the
influence of these survival factors, two of which (margin status and adjuvant therapy receipt) cannot be reliably predicted
with the surgery-first approach.
Despite improvements in modern radiologic imaging, final
pathologic margin status cannot be reliably predicted a priori. This is evident in numerous adjuvant chemotherapy trials
for resectable PDAC that revealed positive margins in 17%–
35% of patients despite strict radiologic enrollment protocols
for anatomically resectable tumors.15,26,27 Although modern
imaging can predict major vascular involvement, it cannot
determine extra-pancreatic extension and microscopic tumor
infiltration, pathologic hallmarks of PDAC. Despite the improved survival outcomes with adjuvant chemotherapy, these

same trials have demonstrated that a significant proportion
of patients do not ever receive or complete systemic therapy
postoperatively for a variety of reasons (38% in CONKO-001,
50% in ESPAC-I, and 43% in ESPAC III).15,26,27 Although
CA19-9 levels can be ascertained at diagnosis and prior to
treatment, and its impact on survival is well known, unfortunately to date these findings have not led to significantly
altered treatment guidelines.9
Aside from the clear survival benefit conveyed by the pursuit of ITT neoadjuvant therapy at the time of diagnosis, the
data presented here also suggest that ITT neoadjuvant therapy
is associated with improvement in other predictors of postoperative survival which may contribute to the overall impact.
In spite of a higher rate of clinically positive nodes, the ITT
neoadjuvant cohort had a lower rate of node positivity on final
pathology, suggesting the treatment effect. Node status is a
clearly established predictor of worse survival—as evidenced
by its presence in the AJCC staging system. Additionally, the
rates of pathologic high grade and lymphovascular invasion
were lower in the ITT neoadjuvant group, which may suggest
treatment effect and the concomitant impact on long-term
survival, or could be due to selection. Finally, it is noteworthy
that patients treated in ITT-neoadjuvant fashion in this study
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FIGURE 2
analysis
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Unadjusted survival

were more commonly clinical stage II and had longer survival
in spite of this, suggesting an actual inversion of the staging
system associated with neoadjuvant therapy. This suggests
that for patients treated with a neoadjuvant approach, modifications to the staging system may be warranted.32,33
It is noteworthy that the dropout rate from ITT neoadjuvant therapy in this study was very low and may not accurately represent the true dropout rate given the limitations
associated with such national datasets. There is a paucity of
existing literature on dropout frequency after neoadjuvant
therapy administration in resectable pancreatic cancer. The
recent SWOG-S1505 trial abstract presented at ASCO 2020
had approximately 6% dropout after neoadjuvant chemotherapy initiation but prior to resection.34 The publication of more
data on the rate of progression in clinically resectable pancreatic cancer patients treated with ITT neoadjuvant therapy is
needed to understand the risks associated with this approach.
The best method for evaluating therapeutic efficacy in oncologic care has traditionally been the randomized controlled

trial, which is viewed as the ‘gold standard’ of clinical evidence. However, in recent years, there is a growing recognition that trials can hinder our understanding of oncologic
disease due to their cost, time required to execute, and the
challenge of blinding patients to interventions such as neoadjuvant chemotherapy versus UFS as well as creating an optimal design to avoid confounding.35–37 Although randomized
trials of UFS versus neoadjuvant systemic chemotherapy are
being conducted, they are not blinded and their generalizability may be limited. In contrast, the utilization of observational ‘big data’ sources such as the NCDB can facilitate
understanding of how treatment decisions can be optimized
based on true ‘real world’ evidence. Although there is significant bias and confounding in these types of studies, there is
growing recognition that well-designed studies utilizing observational data can provide strong insight into clinical best
practices in oncology.38 Real-world observational data such
as these are useful for understanding actual practice patterns
and realized outcomes and should be utilized to inform the

8
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F I G U R E 3 Adjusted proportional
hazards survival model

design and enrollment criteria for future randomized study
protocols.39 In this way, retrospective analysis of ‘big data’
such as these can help advance the ‘gold standard’ in pancreatic cancer care.
Furthermore, the use of randomization to study oncologic
therapy has major limitations which are often overlooked:
fundamental flaws in design, limited power, and problems
with randomization execution. For example, although the recently presented SWOG-S1505 data demonstrate the feasibility of producing high-quality randomized data in this field,
the fact that the study took 5 years to produce and did not
demonstrate a clear ‘winner’ despite the ‘pick the winner’
design provides evidence of the limitations of studying cancer therapeutics using the methodology of randomization.34
Additionally, the ESPAC-5F results failed to demonstrate
a clear clinical difference, showing that even with national
scope in a country with 70 million inhabitants over 4 years,
there is insufficient accrual to execute a randomized study
with four therapy arms and show a clinically meaningful difference.40 If randomization is the only method used to study
pancreatic cancer, there will be many more years and patients
lost before a high-quality answer to the question of whether
UFS or neoadjuvant chemotherapy is a better treatment for
patients with resectable pancreatic cancer is available. In the
meantime, the data presented here can provide valuable perspective for clinical decision making both for the surgeon and
the patient. The question posed should not be ‘is UFS better
than neoadjuvant chemotherapy in resectable PDAC’ in general, but rather what is the quantitative proportional benefit
and odds for patients based on various known and established
survival factors with an upfront surgical approach. Our data
would suggest that survival is realistically far worse and

durable survival is less likely than perceived in the context of
this survival-factor-based analysis.

4.1
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Limitations

This study is limited by its retrospective and non-randomized
nature. We have attempted to utilize careful cohort selection and outlier exclusion to reduce the effects of selection
bias and provide transparency into the sources of bias present in our analysis. NCDB does not provide data on the
completion of non-surgical therapy therefore we cannot ascertain the completeness of chemotherapy and/or radiation
treatment. Clinical staging data in the NCDB—as with all
secondary data sources—may be incomplete or inaccurate,
thus impacting the results of this analysis. Surgery-specific
complication data such as post-operative pancreatic fistula
or delayed gastric emptying are not available although these
are some of the main contributing factors to non-receipt of
adjuvant therapy in this population. Only one CA 19-9 level
is provided in the NCDB, with limited granularity as we have
previously described.12 However, the date when it was measured is not included, nor is this field a required field, and it is
missing in many cases. Therefore, there is no way to utilize
multiple CA 19-9 levels to measure for example treatment
response. Data on the exact type of systemic chemotherapy
and quantification of therapy administered are lacking in the
NCDB, precluding analysis of the extent of systemic therapy
administered. Completeness of the pathologic analysis is not
possible to assess based on the data available in the NCDB.
Finally, there is no data in NCDB on the utilization of salvage
systemic therapy in response to recurrence or progression.
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CO NC LUS ION

Complete surgical extirpation followed by adjuvant systemic
chemotherapy remains the ‘gold standard’ therapy for resectable pancreatic cancer. In spite of the perception that this
surgery-first strategy in ‘resectable’ PDAC is maximally beneficial, only 1-in-5 patients are able to achieve maximal oncologic benefit when assessed in the context of three known
survival factors: negative margins, normal CA19-9, and receipt of adjuvant chemotherapy. Survival decreases with
each failing factor, two of which cannot be predicted prior to
surgery (margin status, adjuvant therapy). When assessed by
these factors, patients with resectable tumors treated with a
surgery-first approach are more likely to have the worst rather
than the best survival outcomes. Similarly staged patients undergoing ITT-neoadjuvant therapy can achieve survival outcomes superior to the majority of patients treated with the
surgery-first approach. Patients should be counseled regarding
their actual probability of achieving maximal survival benefit
rather than the perceived probability when discussing options
for therapeutic sequencing. Further investigation is needed to
critically re-assess the perceived benefit compared to actual
outcomes in a surgery-first treatment paradigm for resectable
PDAC with less focus on resection itself as an arbitrary metric
of oncologic success and more attention paid to specific and
established predictive factors of surgery outcomes.
ETHICS STATEMENT
The Mayo Clinic Institutional Review Board has deemed
analysis of the NCDB PUF exempt from review, and a
blinded statement to this effect is in the methods section of
the manuscript.
ACKNOWLEDGEMENTS
The NCDB is a joint project of the Commission on Cancer of
the American College of Surgeons and the American Cancer
Society. The data used are derived from a de-
identified
NCDB participant user file. The American College of
Surgeons and the Commission on Cancer have not verified
and are not responsible for the analytic or statistical methods
or the conclusions drawn from these data by the investigators.
Additionally, we would like to thank the Society of Surgery
of the Alimentary Tract and the Pancreas Club for affording us the opportunity to present this work at their annual
meetings.
CONFLICT OF INTEREST
All authors disclose no conflict of interest related to this
work.
AUTHOR CONTRIBUTIONS
Bergquist participated in the conception, design, acquisition of data, analysis, and interpretation. Thiels, Shubert,

|

9

Ivanics participated in the design, analysis, and interpretation. Habermann, Vege, Grotz, Cleary, Smoot, Kendrick,
and Nagorney participated in the interpretation of the data.
Truty participated in the conception, design, and interpretation. All authors participated in drafting the article and gave
final approval.
DATA AVAILABILIT Y STATEMENT
The data that support the findings of this study are available
from the Commission on Cancer. Restrictions apply to the
availability of these data, which were used under license
for this study. Data are available by direct request to the
Commission on Cancer/NCDB.
ORCID
John R. Bergquist https://orcid.org/0000-0002-4142-4905
Cornelius A. Thiels https://orcid.
org/0000-0003-3654-8601
R E F E R E NC E S

1. Kleeff J, Korc M, Apte M, et al. Pancreatic cancer. Nat Rev Dis
Prim. 2016;2:16022. https://doi.org/10.1038/nrdp.2016.22.
2. Nishio K, Kimura K, Amano R, et al. Preoperative predictors for early recurrence of resectable pancreatic cancer. World
J Surg Oncol. 2017;15(1):16. https://doi.org/10.1186/s1295
7-016-1078-z.
3. Katz MHG, Pisters PWT, Evans DB, et al. Borderline resectable
pancreatic cancer: the importance of this emerging stage of disease.
J Am Coll Surg. 2008;206(5):833-838. https://doi.org/10.1016/j.
jamcollsurg.2007.12.020.
4. Lee AJ, Simoneau E, Chiang Y-J, et al. Is early-stage pancreatic
adenocarcinoma truly early: stage migration on final pathology
with surgery-first versus neoadjuvant therapy sequencing. HPB.
2019;21(9):1203-1210. https://doi.org/10.1016/j.hpb.2019.01.011.
5. Mokdad AA, Minter RM, Zhu H, et al. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol.
2017;35(5):515-522. https://doi.org/10.1200/JCO.2016.68.5081.
6. Bergquist JR, Shubert CR, Storlie CB, Habermann EB, Truty
MJ. Patient selection for neoadjuvant therapy in early-stage pancreatic cancer. J Clin Oncol. 2017;35(14):1622-1623. https://doi.
org/10.1200/JCO.2016.71.2315.
7. Tummers WS, Groen JV, Sibinga Mulder BG, et al. Impact of
resection margin status on recurrence and survival in pancreatic
cancer surgery. Br J Surg. 2019;106(8):1055-
1065. https://doi.
org/10.1002/bjs.11115.
8. Ghaneh P, Kleeff J, Halloran CM, et al. The impact of positive resection margins on survival and recurrence following resection and
adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Ann
Surg. 2019;269(3):520-
529. https://doi.org/10.1097/SLA.00000
00000002557.
9. Hartwig W, Strobel O, Hinz U, et al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol. 2013;20:2188-2196. https://doi.
org/10.1245/s10434-012-2809-1.
10. Kondo N, Murakami Y, Uemura K, et al. Prognostic impact of
perioperative serum CA 19-9 levels in patients with resectable

10

11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

21.

22.

23.

|

  

pancreatic cancer. Ann Surg Oncol. 2010;17(9):2321-2329. https://
doi.org/10.1245/s10434-010-1033-0.
Barton JG, Bois JP, Sarr MG, et al. Predictive and prognostic value of CA 19–9 in resected pancreatic adenocarcinoma. J
Gastrointest Surg. 2009;13:2050-
2058. https://doi.org/10.1007/
s11605-009-0849-z.
Bergquist JR, Puig CA, Shubert CR, et al. Carbohydrate antigen
19–9 elevation in anatomically resectable, early-stage pancreatic
cancer is independently associated with decreased overall survival and an indication for neoadjuvant therapy: a national cancer
database study. J Am Coll Surg. 2016;223(1):52-65. https://doi.
org/10.1016/j.jamcollsurg.2016.02.009.
Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of
the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4(6):567-579.
Murakami Y, Uemura K, Sudo T, et al. Early initiation of adjuvant chemotherapy improves survival of patients with pancreatic
carcinoma after surgical resection. Cancer Chemother Pharmacol.
2013;71(2):419-429. https://doi.org/10.1007/s00280-012-2029-1.
Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients
with resected pancreatic cancer: the CONKO-
001 randomized
trial. JAMA. 2013;310(14):1473-
1481. https://doi.org/10.1001/
jama.2013.279201.
Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in
pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl
J Med. 2013;369(18):1691-1703. https://doi.org/10.1056/NEJMo
a1304369.
Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J
Med. 2011;364(19):1817-
1825. https://doi.org/10.1056/NEJMo
a1011923.
Dhir M, Malhotra GK, Sohal DPS, et al. Neoadjuvant treatment of
pancreatic adenocarcinoma: a systematic review and meta-analysis
of 5520 patients. World J Surg Oncol. 2017;15(1):183. https://doi.
org/10.1186/s12957-017-1240-2.
Liao W-C, Chien K-L, Lin Y-L, et al. Adjuvant treatments for
resected pancreatic adenocarcinoma: a systematic review and
network meta-analysis. Lancet Oncol. 2013;14(11):1095-1103.
https://doi.org/10.1016/S1470-2045(13)70388-7.
Shubert CR, Bergquist JR, Groeschl RT, et al. Overall survival
is increased among stage III pancreatic adenocarcinoma patients
receiving neoadjuvant chemotherapy compared to surgery first
and adjuvant chemotherapy: an intention to treat analysis of the
National Cancer Database. Surgery. 2016;160(4):1080-1096.
https://doi.org/10.1016/j.surg.2016.06.010.
Mirkin KA, Hollenbeak CS, Wong J. Survival impact of neoadjuvant therapy in resected pancreatic cancer: a prospective cohort study involving 18,332 patients from the National Cancer
Data Base. Int J Surg. 2016;34:96-102. https://doi.org/10.1016/j.
ijsu.2016.08.523.
Shridhar R, Takahashi C, Huston J, Meredith KL. Neoadjuvant
therapy and pancreatic cancer: a national cancer database analysis. J Gastrointest Oncol. 2019;10(4):663-
673. https://doi.
org/10.21037/jgo.2019.02.09.
Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National
Cancer Data Base: a powerful initiative to improve cancer care in
the United States. Ann Surg Oncol. 2008;15(3):683-690. https://
doi.org/10.1245/s10434-007-9747-3.

BERGQUIST et al.

24. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP,
Talamonti MS. National failure to operate on early stage pancreatic
cancer. Ann Surg. 2007;246(2):173-180. https://doi.org/10.1097/
SLA.0b013e3180691579.
25. Ansari D, Gustafsson A, Andersson R. Update on the management
of pancreatic cancer: surgery is not enough. World J Gastroenterol.
2015;21(11):3157-3165.
https://doi.org/10.3748/wjg.v21.
i11.3157.
26. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial
of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200-1210. https://doi.
org/10.1056/NEJMoa032295.
27. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled
trial. JAMA. 2010;304(10):1073-
1081. https://doi.org/10.1001/
jama.2010.1275.
28. Walston S, Salloum J, Grieco C, et al. Identifying clinical factors which predict for early failure patterns following resection for pancreatic adenocarcinoma in patients who received
adjuvant chemotherapy without chemoradiation. Am J Clin Oncol.
2018;41(12):1185-1192.
https://doi.org/10.1097/COC.00000
00000000452.
29. Raigani S, Ammori J, Kim J, Hardacre JM. Trends in the treatment
of resectable pancreatic adenocarcinoma. J Gastrointest Surg.
2014;18(1):113-123. https://doi.org/10.1007/s11605-013-2335-x.
30. Ostapoff KT, Gabriel E, Attwood K, Kuvshinoff BW, Nurkin SJ,
Hochwald SN. Does adjuvant therapy improve overall survival for
stage IA/B pancreatic adenocarcinoma? HPB. 2017;19(7):587-
594. https://doi.org/10.1016/j.hpb.2017.03.002.
31. Bergquist JR, Ivanics T, Shubert CR, et al. Type of resection (whipple vs. distal) does not affect the national failure to provide post-
resection adjuvant chemotherapy in localized pancreatic cancer.
Ann Surg Oncol. 2017;24(6):1731-1738. https://doi.org/10.1245/
s10434-016-5762-6.
32. Mittendorf EA, Vila J, Tucker SL, et al. The neo-bioscore update
for staging breast cancer treated with neoadjuvant chemotherapy
incorporation of prognostic biologic factors into staging after treatment. JAMA Oncol. 2016;2(7):929. https://doi.org/10.1001/jamao
ncol.2015.6478.
33. Bergquist JR, Murphy BL, Storlie CB, Habermann EB, Boughey
JC. Incorporation of treatment response, tumor grade and receptor
status improves staging quality in breast cancer patients treated with
neoadjuvant chemotherapy. Ann Surg Oncol. 2017;24(12):3510-
3517. https://doi.org/10.1245/s10434-017-6010-4.
34. Sohal D, McDonough S, Ahmad SA, et al. SWOG S1505: initial
findings on eligibility and neoadjuvant chemotherapy experience
with mfolfirinox versus gemcitabine/nab-paclitaxel for resectable
pancreatic adenocarcinoma. J Clin Oncol. 2019;37(4_suppl):414.
https://doi.org/10.1200/jco.2019.37.4_suppl.414.
35. Thadhani R. Formal trials versus observational studies. In: Mehta
A, Beck M, Sunder-Plassmann G eds. Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis; 2006.
https://www.ncbi.nlm.nih.gov/books/NBK11597/.
36. Spigel DR. The value of observational cohort studies for cancer
drugs. Biotechnol Healthc. 2010;7(2):18-24.
37. Goulart BHL, Ramsey SD, Parvathaneni U. Observational study
designs for comparative effectiveness research: an alternative approach to close evidence gaps in head-and-neck cancer. Int J Radiat

BERGQUIST et al.

Oncol Biol Phys. 2014;88(1):106-114. https://doi.org/10.1016/j.
ijrobp.2013.05.050.
38. Visvanathan K, Levit LA, Raghavan D, et al. Untapped potential of observational research to inform clinical decision making:
American Society of Clinical Oncology Research statement. J
Clin Oncol. 2017;35(16):1845-
1854. https://doi.org/10.1200/
JCO.2017.72.6414.
39. Bergquist JR, Shah HN, Habermann EB, et al. Adjuvant systemic
therapy after resection of node positive gallbladder cancer: time for
a well-designed trial? (results of a US-national retrospective cohort study). Int J Surg. 2018;52:171-179. https://doi.org/10.1016/j.
ijsu.2018.02.052.
40. Ghaneh P, Palmer DH, Cicconi S, et al. ESPAC-5F: four-arm,
prospective, multicenter, international randomized phase II

  

|

11

trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or
chemoradiotherapy (CRT) in patients with borderline resectable pan. J Clin Oncol. 2020;38:4505. https://doi.org/10.1200/
jco.2020.38.15_suppl.4505.

How to cite this article: Bergquist JR, Thiels CA,
Shubert CR, et al. Perception versus reality: A
National Cohort Analysis of the surgery-first approach
for resectable pancreatic cancer. Cancer Med.
2021;00:1–11. https://doi.org/10.1002/cam4.4144

